These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23722323)

  • 21. Cerebrospinal fluid interleukin-6 in central nervous system inflammatory diseases.
    Wullschleger A; Kapina V; Molnarfi N; Courvoisier DS; Seebach JD; Santiago-Raber ML; Hochstrasser DF; Lalive PH
    PLoS One; 2013; 8(8):e72399. PubMed ID: 24015240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CSF levels of HoxB3 and YKL-40 may predict conversion from clinically isolated syndrome to relapsing remitting multiple sclerosis.
    Tamam Y; Gunes B; Akbayir E; Kizilay T; Karaaslan Z; Koral G; Duzel B; Kucukali CI; Gunduz T; Kurtuncu M; Yilmaz V; Tuzun E; Turkoglu R
    Mult Scler Relat Disord; 2021 Feb; 48():102697. PubMed ID: 33352356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple sclerosis risk genotypes correlate with an elevated cerebrospinal fluid level of the suggested prognostic marker CXCL13.
    Lindén M; Khademi M; Lima Bomfim I; Piehl F; Jagodic M; Kockum I; Olsson T
    Mult Scler; 2013 Jun; 19(7):863-70. PubMed ID: 23175382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative study of CSF neurofilament light and heavy chain protein in MS.
    Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L
    Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of leukemia inhibitory factor in the cerebrospinal fluid of patients with multiple sclerosis.
    Mashayekhi F; Salehi Z
    J Clin Neurosci; 2011 Jul; 18(7):951-4. PubMed ID: 21570299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis.
    Fialová L; Bartos A; Svarcová J; Zimova D; Kotoucova J; Malbohan I
    J Neuroimmunol; 2013 Sep; 262(1-2):113-20. PubMed ID: 23870535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of fractalkine (CX3CL1) in regulation of CD4(+) cell migration to the central nervous system in patients with relapsing-remitting multiple sclerosis.
    Blauth K; Zhang X; Chopra M; Rogan S; Markovic-Plese S
    Clin Immunol; 2015 Apr; 157(2):121-32. PubMed ID: 25596452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oxylipins in cerebrospinal fluid in clinically isolated syndrome and relapsing remitting multiple sclerosis.
    Håkansson I; Gouveia-Figueira S; Ernerudh J; Vrethem M; Ghafouri N; Ghafouri B; Nording M
    Prostaglandins Other Lipid Mediat; 2018 Sep; 138():41-47. PubMed ID: 30118859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis.
    Fainardi E; Castellazzi M; Tamborino C; Trentini A; Manfrinato MC; Baldi E; Tola MR; Dallocchio F; Granieri E; Bellini T
    Mult Scler; 2009 May; 15(5):547-54. PubMed ID: 19318509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
    Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
    Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis.
    Komori M; Blake A; Greenwood M; Lin YC; Kosa P; Ghazali D; Winokur P; Natrajan M; Wuest SC; Romm E; Panackal AA; Williamson PR; Wu T; Bielekova B
    Ann Neurol; 2015 Jul; 78(1):3-20. PubMed ID: 25808056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relapsing-Remitting Multiple Sclerosis diagnosis from cerebrospinal fluids via Fourier transform infrared spectroscopy coupled with multivariate analysis.
    Yonar D; Ocek L; Tiftikcioglu BI; Zorlu Y; Severcan F
    Sci Rep; 2018 Jan; 8(1):1025. PubMed ID: 29348591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebrospinal fluid proteome profile in multiple sclerosis.
    Lehmensiek V; Süssmuth SD; Tauscher G; Brettschneider J; Felk S; Gillardon F; Tumani H
    Mult Scler; 2007 Aug; 13(7):840-9. PubMed ID: 17881397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation.
    Bielekova B; Komori M; Xu Q; Reich DS; Wu T
    PLoS One; 2012; 7(11):e48370. PubMed ID: 23226202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The predictive value of CSF multiple assay in multiple sclerosis: A single center experience.
    De Fino C; Lucchini M; Lucchetti D; Nociti V; Losavio FA; Bianco A; Colella F; Ricciardi-Tenore C; Sgambato A; Mirabella M
    Mult Scler Relat Disord; 2019 Oct; 35():176-181. PubMed ID: 31394405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing-remitting multiple sclerosis.
    Fainardi E; Rizzo R; Melchiorri L; Stignani M; Castellazzi M; Tamborino C; Paolino E; Tola MR; Granieri E; Baricordi OR
    Mult Scler; 2008 May; 14(4):446-54. PubMed ID: 18208868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study.
    Zanghì A; Manuti V; Serviddio G; D'Amico E; Avolio C
    Front Immunol; 2023; 14():1226130. PubMed ID: 37711630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel cerebrospinal fluid and serum autoantibody targets for clinically isolated syndrome.
    Rouwette M; Somers K; Govarts C; De Deyn PP; Hupperts R; Van Wijmeersch B; De Jong BA; Verbeek MM; Van Pesch V; Sindic C; Villar LM; Álvarez-Cermeño JC; Stinissen P; Somers V
    J Neurochem; 2012 Nov; 123(4):568-77. PubMed ID: 22958230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis.
    Schwarz M; Spector L; Gortler M; Weisshaus O; Glass-Marmor L; Karni A; Dotan N; Miller A
    J Neurol Sci; 2006 May; 244(1-2):59-68. PubMed ID: 16480743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis.
    Acaster S; Swinburn P; Wang C; Stemper B; Beckmann K; Knappertz V; Pohl C; Sandbrink R; Gondek K; Edan G; Kappos L; Freedman M; Hartung HP; Arnason B; Comi G; Filippi M; Jeffery D; O'Connor P; Cook S; Lloyd AJ
    Mult Scler; 2011 Dec; 17(12):1504-13. PubMed ID: 21757536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.